Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

Phase 2

Completed

• Conditions: Uterus Leiomyosarcoma; Soft Tissue Leiomyosarcoma
• Interventions: Drug: Doxorubicin; Drug: Trabectedin

• Registration Number: NCT02131480
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

Uterine leiomyosarcomas and soft tissues are rare tumors with a poor prognosis when metastatic or locally advanced. They have an average chemosensitivity mainly to doxorubicin, ifosfamide, cisplatin, gemcitabine and trabectedin but response rates in combination in first line does not exceed 55% for uterine leiomyosarcomas and 35% for leiomyosarcomas of soft tissue.

The trabectedin is a new cancer drug that has obtained marketing authorization after failure of anthracyclines and ifosfamide in the treatment of soft tissue sarcomas (STM) in Europe. It has especially shown efficacy in myxoid liposarcomas, leiomyosarcomas and synoviosarcoma.

This study aims to evaluate the usefulness of the combination of trabectedin with doxorubicin in first-line treatment of uterine or soft tissue leiomyosarcoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06
• Primary Completion: 2013-01
• Study First Submitted: 2014-05-05
• Study First Submitted QC: 2014-05-05
• Study First Posted: 2014-05-06
• Study Completion: 2016-10
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-25
• Last Update Posted: 2017-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

• Metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy
• At least one measurable lesion according to RECIST criteria before inclusion. At least one of the target is in a none irradiated area
• Aged >/= 18 years and physiological age </= 70 years
• PS </= 2
• Normal hematological function (Polymorphonuclear Neutrophils >/= 1500/mm3, platelets >/= 100 000/mm3)
• Normal kidney function (creatinine < 1.5xN)
• Creatinine phosphokinase </= 2.5xN
• Normal hepatic function (total bilirubin </= 1xN; transaminase </= 2.5xN and alkaline phosphatase </= 1.5xN)
• Cardiac function: normal echography and/or isotopic ventriculography (FR>30%, FEVG > 50%)
• Patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men
• Signed informed consent
• Patient under affiliated to a system of care

Exclusion Criteria

• Any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue
• Specific contraindication to the treatment
• Previous or evolutive mental disease
• Previous cancer
• Symptomatic or known brain metastasis
• Previous radiotherapy ont he only measurable lesion
• Previous allograft or autograft
• Known positive serology (HIV, HbC, HbS)
• Pregnant or breastfeeding women
• Impossibility to follow the treatment for geographical, social or mental reason
• Patients under legal protection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Soft tissue	Doxorubicin	-
Soft tissue	Trabectedin	-
Uterus	Doxorubicin	-
Uterus	Trabectedin	-

Primary Outcome Measures

Name	Time	Method
Disease control rate	Assessed every 6 weeks from inclusion up to 6 months	Disease control rate (objective response + stability) as defined by RECIST criteria

Secondary Outcome Measures

Name	Time	Method
Response rate	Assessed every 6 weeks from inclusion up to 6 months	Assessed using RECIST criteria
Progression Free Survival	Assessed every 6 weeks from inclusion up to 12 weeks

Trial Locations

Locations (1)

Gustave Roussy Cancer Campus Grand Paris; 🇫🇷 Villejuif, Val de Marne, France